142 related articles for article (PubMed ID: 9359687)
1. TNF inhibition and sepsis -- sounding a cautionary note.
Grau GE; Maennel DN
Nat Med; 1997 Nov; 3(11):1193-5. PubMed ID: 9359687
[No Abstract] [Full Text] [Related]
2. Importance of underlying mechanism and genotype on outcome of sepsis trials.
McIntyre L; Walley KR
Crit Care Med; 2001 Mar; 29(3):677-9. PubMed ID: 11373447
[No Abstract] [Full Text] [Related]
3. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis.
Butty VL; Roux-Lombard P; Garbino J; Dayer JM; Ricou B;
Eur Cytokine Netw; 2003; 14(1):15-9. PubMed ID: 12799209
[TBL] [Abstract][Full Text] [Related]
4. Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways.
Renzetti LM; Gater PR
Inflamm Res; 1997 Aug; 46 Suppl 2():S143-4. PubMed ID: 9297552
[No Abstract] [Full Text] [Related]
5. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
[TBL] [Abstract][Full Text] [Related]
6. Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to tumour necrosis factor alpha blocking treatment.
den Broeder AA; van den Hoogen FH; van de Putte LB
Ann Rheum Dis; 2001 May; 60(5):538-9. PubMed ID: 11302883
[TBL] [Abstract][Full Text] [Related]
7. Cytokine blockade in sepsis--Are two better than one?
Hotchkiss RS; Karl IE
Crit Care Med; 2001 Mar; 29(3):671-2. PubMed ID: 11373443
[No Abstract] [Full Text] [Related]
8. TNF-alpha-targeted therapy in rheumatoid arthritis.
Wendling D; Toussirot E
Rev Rhum Engl Ed; 1999 Apr; 66(4):187-91. PubMed ID: 10339773
[No Abstract] [Full Text] [Related]
9. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.
Harbarth S; Garbino J; Pugin J; Romand JA; Lew D; Pittet D
Am J Med; 2003 Nov; 115(7):529-35. PubMed ID: 14599631
[TBL] [Abstract][Full Text] [Related]
10. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of MHC class I-stimulated alloresponses by TNF/TNF receptor (TNFR)1 interactions and of MHC class II-stimulated alloresponses by TNF/TNFR2 interactions.
Brown GR; Thiele DL
Eur J Immunol; 2000 Oct; 30(10):2900-7. PubMed ID: 11069072
[TBL] [Abstract][Full Text] [Related]
12. USAN Council. List No.407. New names. Lenercept.
Clin Pharmacol Ther; 1998 Aug; 64(2):234. PubMed ID: 9758530
[No Abstract] [Full Text] [Related]
13. Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis.
Quattrocchi E; Walmsley M; Browne K; Williams RO; Marinova-Mutafchieva L; Buurman W; Butler DM; Feldmann M
J Immunol; 1999 Jul; 163(2):1000-9. PubMed ID: 10395698
[TBL] [Abstract][Full Text] [Related]
14. Impact of immunomodulating therapy on morbidity in patients with severe sepsis.
Pittet D; Harbarth S; Suter PM; Reinhart K; Leighton A; Barker C; Macdonald F; Abraham E
Am J Respir Crit Care Med; 1999 Sep; 160(3):852-7. PubMed ID: 10471608
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis.
Murphy CC; Greiner K; Plskova J; Duncan L; Frost A; Isaacs JD; Rebello P; Waldmann H; Hale G; Forrester JV; Dick AD
Arch Ophthalmol; 2004 Jun; 122(6):845-51. PubMed ID: 15197059
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
Feldmann M; Maini RN
Annu Rev Immunol; 2001; 19():163-96. PubMed ID: 11244034
[TBL] [Abstract][Full Text] [Related]
17. Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality.
Remick DG; Call DR; Ebong SJ; Newcomb DE; Nybom P; Nemzek JA; Bolgos GE
Crit Care Med; 2001 Mar; 29(3):473-81. PubMed ID: 11373406
[TBL] [Abstract][Full Text] [Related]
18. Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein.
Sumbria RK; Boado RJ; Pardridge WM
J Cereb Blood Flow Metab; 2012 Oct; 32(10):1933-8. PubMed ID: 22714051
[TBL] [Abstract][Full Text] [Related]
19. Focus on: biologics that affect therapeutic agents in dermatology.
Saripalli YV; Gaspari AA
J Drugs Dermatol; 2005; 4(2):233-45. PubMed ID: 15776786
[TBL] [Abstract][Full Text] [Related]
20. Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways.
Gater PR; Renzetti LM
Agents Actions Suppl; 1998; 49():67-71. PubMed ID: 9426830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
